iCrowdNewswire Nov 3, 202010:25 AM ET
The exosome diagnostic and therapeutic market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027.
Exosomes are nano-vesicles that constitute proteins, DNA, and RNA. Exosomes play an important role in aiding cell-to-cell communication while diagnosing cancer. It lowers the body’s immune function by stimulating programmed cell death of activated cytotoxic T-cells, which modify neoplasm progression within the human body. The exosome diagnostic and therapeutic market is expected to witness huge growth due to greater precision and advantages over traditional methods of diagnosis and therapeutics. However, poor infrastructure and lack of expertise required for isolation of exosomes may hinder the market growth.
Get sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005514/
Leading companies operating in the exosome diagnostic and therapeutic market are Aethlon Medical, Inc., Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, Cell Guidance Systems LLC, BioRegenerative Sciences, Evomic Science LLC, NorgenBiotek Corp., Exosome Diagnostics, Inc./Bio-Techne, and MiltenyiBiotec, among others.
The global exosome diagnostic and therapeutic market, based on application, is further segmented into diagnostic and therapeutic. The diagnostic segment held a larger share of the market in 2019. Also, the diagnostic segment is estimated to register a higher CAGR during the forecast period owing to increasing adoption to exosomes for the diagnosis of chronic conditions and increasing awareness of procedural outcomes served by exosomes. Increasing awareness about exosomes diagnostics is propelling the companies to enter into this market to tap lucrative opportunities. For instance, in March 2016, Sysmex and JVCKENWOOD launched a joint program for the development of diagnostic instruments for measurement of exosomes.
These tiny particles carry cellular nucleic acids and proteins from their host cells to target cells, which represent the comprehensive information about pathophysiological conditions of the host cell. For instance, exosomes released from tumor cells contains tumor-specific RNAs that can be potentially detected during cancer diagnosis. These carrier exosomes can also be used as biomarkers in the diagnosis of neurodegenerative and metabolic disorders, and infectious and other diseases. Additionally, the presence of exosomes in body fluids such as saliva and urine islikely to rule out the traditional methods involving the collection of the invasive body fluids.Thus, the growing emphasis on clinically noninvasive diagnosis is likely to drive the adoption of exosomes-based diagnosis and therapeutics in the medical industry during the forecast period.
Exosome Diagnostic and Therapeutic Market – ByApplication
Exosome Diagnostic and Therapeutic Market – By Product
Exosome Diagnostic and Therapeutic Market – By End User
- Cancer Institutes
- Diagnostic Centers
Exosome Diagnostic and Therapeutic Market– By Geography
- North America
- Rest of Europe
- Asia Pacific(APAC)
- South Korea
- Rest of APAC
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
- South America (SAM)
- Rest of SAM
Purchase This Report at: https://www.theinsightpartners.com/buy/TIPRE00005514/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Keywords: Exosome Diagnostics and Therapeutic Market, Exosome Diagnostics and Therapeutic, Exosome Diagnostics and Therapeutic Market growth, Exosome Diagnostics and Therapeutic Market demand, Exosome Diagnostics and Therapeutic Market share, Exosome Diagnostics and Therapeutic Market analysis